Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 177 clinical trials
featured
RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

  • 230 views
  • 08 Nov, 2020
  • 1 location
featured
  • 228 views
  • 08 Nov, 2020
  • 1 location
Adjuvant Trastuzumab Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer

chemotherapy agent (docetaxel) for a brief duration, and the patients allocated to the comparator group (Group B) will be treated with chemotherapy plus one anti-HER2 treatment (trastuzumab) for one year.

adjuvant therapy
immunohistochemistry
immunostimulant
cish
invasive breast cancer
  • 7 views
  • 04 Nov, 2020
  • 1 location
A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

This study aims to evaluate vinorelbine plus capecitabine combined with trastuzumab versus trastuzumab alone as the adjuvant Treatment of HER2 positive patients following neoadjuvant

cish
immunostimulant
vinorelbine
metastasis
paclitaxel
  • 3 views
  • 15 Mar, 2020
  • 1 location
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I Stage II or Stage III HER2-Positive Breast Cancer

as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing

adjuvant therapy
tumor cells
tamoxifen
immunostimulant
paclitaxel
  • 33 views
  • 07 Nov, 2020
  • 1 location
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

This is a randomized, double-blinded, multicenter phase 3 clinical trial to evaluate the efficacy and safety of pyrotinib plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus

cancer treatment
HER2
metastasis
measurable disease
trastuzumab
  • 0 views
  • 24 Jun, 2020
  • 1 location
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low Hormone Receptor Positive Metastatic Breast Cancer

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low

  • 35 views
  • 17 Jan, 2021
  • 183 locations
Phase Ib Study of the Safety of T-DXd and Durvalumab With Chemotherapy in Advanced or Metastatic HER2+ Non-squamous NSCLC

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with chemotherapy in patients with HER2 positive advanced and metastatic non-small lung

  • 0 views
  • 18 Jan, 2021
  • 20 locations
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

n the present study the neoadjuvant approach with the anti-HER2 trastuzumab and pertuzumab combined with carboplatin and paclitaxel will be used to compare the Event-Free Survival (EFS) in

sentinel node
atezolizumab
paclitaxel
tubal ligation
residual tumor
  • 17 views
  • 12 Aug, 2019
  • 35 locations
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

This study is a randomized, single center, phase III clinical trial comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of docetaxel (EC4-T4) verses 6 cycles of weekly paclitaxel combined with carboplatin (PCb*6) in the adjuvant chemotherapy of non-triple negative breast cancer …

epidermal growth factor receptor
immunohistochemistry
paclitaxel
immunostimulant
cish
  • 2 views
  • 15 Mar, 2020
  • 1 location